Related Experiment Video
Updated: Nov 8, 2025

In vitro Organoid Culture of Primary Mouse Colon Tumors
Published on: May 17, 2013
RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways
Victoria Gudiño1,2, Sebastian Öther-Gee Pohl1, Caroline V Billard1
1Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, The University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK.
Abstract:
Current therapeutic options for treating colorectal cancer have little clinical efficacy and acquired resistance during treatment is common, even following patient stratification. Understanding the mechanisms that promote therapy resistance may lead to the development of novel therapeutic options that complement existing treatments and improve patient outcome. Here, we identify RAC1B as an important mediator of colorectal tumourigenesis and a potential target for enhancing the efficacy of EGFR inhibitor treatment. We find that high RAC1B expression in human colorectal cancer is associated with aggressive disease and poor prognosis and deletion of Rac1b in a mouse colorectal cancer model reduces tumourigenesis. We demonstrate that RAC1B interacts with, and is required for efficient activation of the EGFR signalling pathway. Moreover, RAC1B inhibition sensitises cetuximab resistant human tumour organoids to the effects of EGFR inhibition, outlining a potential therapeutic target for improving the clinical efficacy of EGFR inhibitors in colorectal cancer.
Insights
RAC1B promotes colorectal cancer growth and resistance to EGFR inhibitors. Inhibiting RAC1B may improve treatment efficacy for patients with colorectal cancer, enhancing outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Colorectal cancer (CRC) treatments often lack efficacy and develop resistance.
- Understanding resistance mechanisms is crucial for developing improved therapies.
Purpose of the Study:
- Identify novel therapeutic targets to overcome CRC treatment resistance.
- Investigate the role of RAC1B in colorectal tumorigenesis and EGFR inhibitor resistance.
Main Methods:
- Analyzed RAC1B expression in human CRC tissues.
- Utilized a mouse model of colorectal cancer with Rac1b deletion.
- Examined RAC1B's interaction with the EGFR signaling pathway.
- Assessed RAC1B inhibition in cetuximab-resistant CRC organoids.
Main Results:
- High RAC1B expression correlates with aggressive CRC and poor prognosis.
- Rac1b deletion in mice reduced colorectal tumor development.
- RAC1B is essential for efficient EGFR pathway activation.
- Inhibiting RAC1B resensitized resistant CRC organoids to EGFR inhibitors.
Conclusions:
- RAC1B is a key mediator of colorectal tumorigenesis and therapy resistance.
- Targeting RAC1B presents a promising strategy to enhance EGFR inhibitor efficacy in CRC.
Related Concept Videos
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Canonical Wnt Signaling Pathway
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...
Non-Canonical Wnt Signaling Pathways

